Polatuzumab Vedotin With Infusional Chemotherapy for Untreated Aggressive B-Cell Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Polatuzumab vedotin with infusional chemotherapy (Pola-DA-EPCH-R) for untreated aggressive B-cell non-Hodgkin lymphomas
Blood Adv 2022 Dec 15;[EPub Ahead of Print], RC Lynch, C Poh, CS Ujjani, EH Warren, SD Smith, M Shadman, K Morris, S Lee, H Rasmussen, S Ottemiller, M Shelby, S Keo, K Verni, DM Kurtz, AA Alizadeh, JJ Chabon, GJ Hogan, A Schulz, TA Gooley, JM Voutsinas, AK GopalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.